Lori W.’s Post

#GLP1s have become the #drugclass of choice in the weight loss category. In this MedTalks Minute, hear MedImpact Healthcare Systems, Inc.'s VP of #Clinical Services discuss the current landscape of these popular drugs. Stay tuned for Part Two to hear what #payers need to know! #wearemedimpact #atruepartner #weightmanagement #drugtrends #medtalksminute

#GLP1s have become the #drugclass of choice in the weight loss category. In this MedTalks Minute, hear MedImpact Healthcare Systems, Inc.'s VP of #Clinical Services discuss the current landscape of these popular drugs. Stay tuned for Part Two to hear what #payers need to know! #wearemedimpact #atruepartner #weightmanagement #drugtrends #medtalksminute

#GLP1s have become the #drugclass of choice in the weight loss category. In this MedTalks Minute, hear MedImpact Healthcare Systems, Inc.'s VP of #Clinical Services discuss the current landscape of these popular drugs. Stay tuned for Part Two to hear what #payers need to know! #wearemedimpact #atruepartner #weightmanagement #drugtrends #medtalksminute

#GLP1s have become the #drugclass of choice in the weight loss category. In this MedTalks Minute, hear MedImpact Healthcare Systems, Inc.'s VP of #Clinical Services discuss the current landscape of these popular drugs. Stay tuned for Part Two to hear what #payers need to know! #wearemedimpact #atruepartner #weightmanagement #drugtrends #medtalksminute

#GLP1s have become the #drugclass of choice in the weight loss category. In this MedTalks Minute, hear MedImpact Healthcare Systems, Inc.'s VP of #Clinical Services discuss the current landscape of these popular drugs. Stay tuned for Part Two to hear what #payers need to know! #wearemedimpact #atruepartner #weightmanagement #drugtrends #medtalksminute

#GLP1s have become the #drugclass of choice in the weight loss category. In this MedTalks Minute, hear MedImpact Healthcare Systems, Inc.'s VP of #Clinical Services discuss the current landscape of these popular drugs. Stay tuned for #PartTwo to hear what #payers need to know! #wearemedimpact #atruepartner #weightmanagement #drugtrends #medtalksminute #pbm

While cost-sharing can be expressed as a well-intended benefit design, it can negatively affect long-term drug adherence by patients. AMCP supports efforts to reduce out-of-pocket costs where appropriate, including provisions of the Inflation Reduction Act. However, there could be long-term and unintended consequences in reducing premiums, so it is crucial to develop comprehensive and patient-centric solutions to address these issues over time. AMCP, along with our partners, look forward to our continued efforts to address these complex solutions. https://bit.ly/3T6LSFH #drugpricing #healthequity #patientaccess

The surge in popularity of GLP-1 medications like Ozempic and Wegovy for weight management is exciting, but current data reveals a critical issue: over 30% of patients drop treatment within four weeks. As healthcare marketers, we must address this gap by enhancing our patient education and support strategies. Understanding the role of healthcare providers in fostering adherence is key. Let’s strategize on building comprehensive care models that keep patients engaged long-term. #HealthcareMarketing #PatientEngagement

According to The State of Drug Diversion 2023 Report, there are still many opportunities for drug diversion awareness within our health systems, as many facilities are still highly dependent on internal audits, anonymous tips and Automated Dispensing Cabinet (ADC) reports. Read more in this Pharmacy Times article by our own Stacey McCoy, PharmD, MS, BCPS. https://ow.ly/lZyO50QnxNY

In a new open letter, EmpiRx Health CEO Danny S. addresses the bipartisan election year issue of skyrocketing drug costs. The PBM industry was founded more than a half-century ago to help manage these costs, but it has not exactly worked out that way. As legislators and regulators increasingly criticize the traditional volume-driven PBM operating model, there’s a growing drumbeat around PBM “transparency” as the solution to the massive problem of rising drug costs. But, as Sanchez notes in his open letter, “transparency is just one step” in the vital push for PBM reform.     What’s really needed is the broader adoption of a clinically-driven approach to pharmacy care that puts the pharmacist back in pharmacy benefits management. Want to learn more about the clinically-driven PBM reform revolution? Read the entire open letter here: https://lnkd.in/eAAKtpJR #OpenLetter #PBM #Legislators #ClinicallyDriven